Ranolazine

Generic Name
Ranolazine
Brand Names
Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
Drug Type
Small Molecule
Chemical Formula
C24H33N3O4
CAS Number
95635-55-5
Unique Ingredient Identifier
A6IEZ5M406
Background

Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drug...

Indication

Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
...

Associated Conditions
Chronic Angina, Ventricular Arrhythmia
Associated Therapies
-
Clinical Trials
Related News

Ranolazine in Ischemic Cardiomyopathy

Phase 4
Completed
Conditions
Cardiomyopathy
Dyspnea
Chest Pain
Interventions
Drug: Placebo
Drug: Ranexa
First Posted Date
2011-04-29
Last Posted Date
2024-12-09
Lead Sponsor
Midwest Cardiovascular Research Foundation
Target Recruit Count
28
Registration Number
NCT01345188
Locations
🇺🇸

Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

Not Applicable
Completed
Conditions
Microvascular Coronary Dysfunction (MCD)
Interventions
Drug: Placebo
Drug: Ranolazine
First Posted Date
2011-04-26
Last Posted Date
2019-04-24
Lead Sponsor
Cedars-Sinai Medical Center
Target Recruit Count
142
Registration Number
NCT01342029
Locations
🇺🇸

127 S. San Vicente Blvd, Suite A9303, Los Angeles, California, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

First Posted Date
2011-04-13
Last Posted Date
2012-07-31
Lead Sponsor
Gilead Sciences
Registration Number
NCT01334203

Ranolazine, Ethnicity and the Metabolic Syndrome

First Posted Date
2011-02-25
Last Posted Date
2013-07-11
Lead Sponsor
Atlanta Heart Specialists, LLC
Target Recruit Count
160
Registration Number
NCT01304095
Locations
🇺🇸

Atlanta Heart Specialist, LLC, Cumming, Georgia, United States

🇺🇸

Atlanta Heart Specialists, LLC, Tucker, Georgia, United States

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

First Posted Date
2010-10-14
Last Posted Date
2014-09-03
Lead Sponsor
Gilead Sciences
Target Recruit Count
81
Registration Number
NCT01221272
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

🇨🇦

Chum Hotel Dieu, Montreal, Quebec, Canada

🇫🇮

Turku University Hospital, Turku, Finland

and more 39 locations

Ranolazine Implantable Cardioverter-Defibrillator Trial

First Posted Date
2010-10-06
Last Posted Date
2018-08-27
Lead Sponsor
University of Rochester
Target Recruit Count
1012
Registration Number
NCT01215253
Locations
🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

Hartford Hospital, Hartford, Connecticut, United States

🇺🇸

University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 87 locations

Ranolazine and Pulmonary Hypertension

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
Angina
Interventions
Drug: Ranolazine
First Posted Date
2010-08-03
Last Posted Date
2018-05-11
Lead Sponsor
Northwestern University
Target Recruit Count
11
Registration Number
NCT01174173
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Phase 2
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
Drug: Ranolazine
First Posted Date
2010-07-16
Last Posted Date
2013-09-23
Lead Sponsor
Gilead Sciences
Target Recruit Count
80
Registration Number
NCT01163721
Locations
🇺🇸

National Research Institute (NRI), Los Angeles, California, United States

🇺🇸

Vince and Associates Clinical Research, Overland Park, Kansas, United States

🇺🇸

Cetero Research, San Antonio, Texas, United States

and more 6 locations

Ranolazine in Diastolic Heart Failure

First Posted Date
2010-07-16
Last Posted Date
2012-07-12
Lead Sponsor
Gilead Sciences
Target Recruit Count
20
Registration Number
NCT01163734
Locations
🇩🇪

University Medicine Goettingen (UMG), Goettingen, Germany

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

First Posted Date
2009-10-20
Last Posted Date
2012-02-09
Lead Sponsor
Aspirus Heart and Vascular Institute-Research and Education
Target Recruit Count
7
Registration Number
NCT00998218
Locations
🇺🇸

Aspirus Wausau Hospital, Wausau, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy